Fos-related antigen 1 modulates malignant features of glioma cells

Molecular Cancer Research

Volumn 3, Issue 4, 2005, Pages 237-249

  Debinski, Waldemar ^a   Gibo, Denise M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C FOS; TRANSCRIPTION FACTOR FRA 1; VASCULOTROPIN D;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANTIGEN DETECTION; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER INFILTRATION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; EFFECTOR CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

BRAIN NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOTYPE; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSGENES;

EID: 17144367277     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Levin VA, Sheline GH, Gutin PH. Neoplasms of the central nervous system. 3rd ed. In: Cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott Co.; 1989. p. 1557-611.
2. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
3. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
4. Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000;6:440-9.
5. Guo J, Apiou F, Mellerin M-P, Lebeau B, Jacques Y, Minvielle S. Chromosome mapping and expression of the human interleukin-13 receptor. Genomics 1997;42:141-5.
6. Mintz A, Debinski W. Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies. Crit Rev Oncog 2000;11:77-95.
7. Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 2000;48:103-11.
8. Mintz A, Gibo DM, Slagle-Webb B, Debinski W. IL-13Rα2 is a glioma-restricted receptor for interleukin 13. Neoplasia 2002;4:388-99.
9. Madhankumar AB, Mintz A, Debinski W. Interleukin 13 (IL13) mutants of enhanced targeting of a tumor-associated receptor, IL13Rα-2. Neoplasia 2004;6:15-22.
10. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548-53.
11. Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A 1999;96:9671-6.
12. Debinski W, Slagle-Webb B, Achen MG, et al. VEGF-D is an X-linked/AP-1-regulated onco-angiogen in highly vascularized tumors. Mol Med 2001;7:598-608.
13. Long DM. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 1970;32:127-44.
14. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48:347-56.
15. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
16. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
17. Ransone LJ, Verma IM. Nuclear proto-oncogenes fas and jun. Annu Rev Cell Biol 1990;6:539-57.
18. Ozanne BW, McGarry L, Spence HJ, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000;36:1640-8.
19. Scott LA, Vass JK, Parkinson EK, Gillespie DAF, Winnie JN, Ozanne BW. Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressor p16INK4a and p53. Mol Cell Biol 2004;24:1540-59.
20. Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yagub IZ. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytomas. Am J Pathol 1995;146:1150-60.
21. Yamamoto H, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54:3656-61.
22. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994;54:5016-20.
23. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J-I. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995;83:298-307.
24. Kupferman ME, Fini ME, Muller WJ, Weber R, Cheng Y, Muschel RJ. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 2000;157:1777-83.
25. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 1990;50:7393-8.
26. Paulus W, Grothe C, Sensenbrenner M, et al. Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol (Berl) 1990;79:418-23.
27. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A 1994;91:484-8.
28. Battista S, de Nigris F, Fedele M, et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 1998;17:377-85.
29. Zoumpourlis V, Papassava P, Lindardopoulos S, Gillespie D, Balmain A, Pintzas A. High levels of c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 2000;19:4011-21.
30. Mann B, Gelos M, Siedow A, et al. Target genes of b-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8.
31. Bamberger AM, Methner C, Lisboa BW, et al. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 1999;84:533-8.
32. Tulchinsky E. Fos family members: regulation, structure, and role in oncogenic transformation. Histol Histopathol 2000;15:921-8.
33. Fleischmann A, Hafezi F, Elliott C, Reme CE, Ruther U, Wagner EF. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev 2000;14:2695-700.
34. White JD, Hewett PW, Kosuge D, et al. VEGF-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002;62:1669-75.
35. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res 2003;9:716-21.
36. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003;88:237-44.
37. Schreiber M, Wand Z-Q, Jochum W, Fetka I, Elliott C, Wagner EF. Placental vascularisation requires the AP-1 component Fra-1. Development 2000;127:4937-48.
38. Karin M, Liu Z-G, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
39. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 1995;15:3748-58.
40. Andersen H, Mahmood S, Tkach V, et al. The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials. Oncogene 2002;21:4843-8.
41. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fos11 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000;24:184-7.
42. Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E, Berezin V. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 2003;22:5045-54.
43. Kustikova O, Kramerov D, Grigorian M, et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998;18:7095-105.
44. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003;4:67-79.
45. Myers JN, Yasmura S, Suminami Y, et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 1996;2:127-35.
46. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996;87:929-39.
47. Rauscher FJ, Sambucetti LC, Curran T, Distel RJ, Spiegelman BM. Common DNA binding site for Fos protein complexes and transcription factor AP-1. Cell 1988;52:471-80.
48. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002;8:1740-6.
49. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.